Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern
SARS-CoV-2 infection and/or vaccination elicit a broad range of neutralizing antibody responses against the different variants of concern (VOC). We established a new variant-adapted surrogate virus neutralization test (sVNT) and assessed the neutralization activity against the ancestral B.1 (WT) and...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/19/14965 |
| _version_ | 1797575740022063104 |
|---|---|
| author | Eveline Santos da Silva Jean-Yves Servais Michel Kohnen Vic Arendt Therese Staub the CON-VINCE Consortium the CoVaLux Consortium Rejko Krüger Guy Fagherazzi Paul Wilmes Judith M. Hübschen Markus Ollert Danielle Perez-Bercoff Carole Seguin-Devaux |
| author_facet | Eveline Santos da Silva Jean-Yves Servais Michel Kohnen Vic Arendt Therese Staub the CON-VINCE Consortium the CoVaLux Consortium Rejko Krüger Guy Fagherazzi Paul Wilmes Judith M. Hübschen Markus Ollert Danielle Perez-Bercoff Carole Seguin-Devaux |
| author_sort | Eveline Santos da Silva |
| collection | DOAJ |
| description | SARS-CoV-2 infection and/or vaccination elicit a broad range of neutralizing antibody responses against the different variants of concern (VOC). We established a new variant-adapted surrogate virus neutralization test (sVNT) and assessed the neutralization activity against the ancestral B.1 (WT) and VOC Delta, Omicron BA.1, BA.2, and BA.5. Analytical performances were compared against the respective VOC to the reference virus neutralization test (VNT) and two CE-IVD labeled kits using three different cohorts collected during the COVID-19 waves. Correlation analyses showed moderate to strong correlation for Omicron sub-variants (Spearman’s r = 0.7081 for BA.1, r = 0.7205 for BA.2, and r = 0.6042 for BA.5), and for WT (r = 0.8458) and Delta-sVNT (r = 0.8158), respectively. Comparison of the WT-sVNT performance with two CE-IVD kits, the “Icosagen SARS-CoV-2 Neutralizing Antibody ELISA kit” and the “Genscript cPass, kit” revealed an overall good correlation ranging from 0.8673 to −0.8773 and a midway profile between both commercial kits with 87.76% sensitivity and 90.48% clinical specificity. The BA.2-sVNT performance was similar to the BA.2 Genscript test. Finally, a correlation analysis revealed a strong association (r = 0.8583) between BA.5-sVNT and VNT sVNT using a double-vaccinated cohort (<i>n</i> = 100) and an Omicron-breakthrough infection cohort (<i>n</i> = 91). In conclusion, the sVNT allows for the efficient prediction of immune protection against the various VOCs. |
| first_indexed | 2024-03-10T21:42:34Z |
| format | Article |
| id | doaj.art-3b2f62ad7cbd47de9307f35be9e6928f |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T21:42:34Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-3b2f62ad7cbd47de9307f35be9e6928f2023-11-19T14:33:13ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-10-0124191496510.3390/ijms241914965Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of ConcernEveline Santos da Silva0Jean-Yves Servais1Michel Kohnen2Vic Arendt3Therese Staub4the CON-VINCE Consortiumthe CoVaLux ConsortiumRejko Krüger5Guy Fagherazzi6Paul Wilmes7Judith M. Hübschen8Markus Ollert9Danielle Perez-Bercoff10Carole Seguin-Devaux11Department of Infection and Immunity, Luxembourg Institute of Health, 29 Rue Henri Koch, L-4354 Esch-sur-Alzette, LuxembourgDepartment of Infection and Immunity, Luxembourg Institute of Health, 29 Rue Henri Koch, L-4354 Esch-sur-Alzette, LuxembourgNational Service of Infectious Diseases, Centre Hospitalier de Luxembourg, 4 Rue Ernest Barblé, L-1210 Luxembourg, LuxembourgNational Service of Infectious Diseases, Centre Hospitalier de Luxembourg, 4 Rue Ernest Barblé, L-1210 Luxembourg, LuxembourgNational Service of Infectious Diseases, Centre Hospitalier de Luxembourg, 4 Rue Ernest Barblé, L-1210 Luxembourg, LuxembourgTransversal Translational Medicine, Luxembourg Institute of Health, Centre Hospitalier de Luxembourg, 4 rue Ernest Barblé, L-1210 Luxembourg, LuxembourgDepartment of Precision Health, Luxembourg Institute of Health, 1AB Rue Thomas Edison, L-1445 Strassen, LuxembourgSystems Ecology Group, Luxembourg Centre for Systems Biomedicine, 7 Avenue des Hauts Fourneaux, L-4362 Esch-sur-Alzette, LuxembourgDepartment of Infection and Immunity, Luxembourg Institute of Health, 29 Rue Henri Koch, L-4354 Esch-sur-Alzette, LuxembourgDepartment of Infection and Immunity, Luxembourg Institute of Health, 29 Rue Henri Koch, L-4354 Esch-sur-Alzette, LuxembourgDepartment of Infection and Immunity, Luxembourg Institute of Health, 29 Rue Henri Koch, L-4354 Esch-sur-Alzette, LuxembourgDepartment of Infection and Immunity, Luxembourg Institute of Health, 29 Rue Henri Koch, L-4354 Esch-sur-Alzette, LuxembourgSARS-CoV-2 infection and/or vaccination elicit a broad range of neutralizing antibody responses against the different variants of concern (VOC). We established a new variant-adapted surrogate virus neutralization test (sVNT) and assessed the neutralization activity against the ancestral B.1 (WT) and VOC Delta, Omicron BA.1, BA.2, and BA.5. Analytical performances were compared against the respective VOC to the reference virus neutralization test (VNT) and two CE-IVD labeled kits using three different cohorts collected during the COVID-19 waves. Correlation analyses showed moderate to strong correlation for Omicron sub-variants (Spearman’s r = 0.7081 for BA.1, r = 0.7205 for BA.2, and r = 0.6042 for BA.5), and for WT (r = 0.8458) and Delta-sVNT (r = 0.8158), respectively. Comparison of the WT-sVNT performance with two CE-IVD kits, the “Icosagen SARS-CoV-2 Neutralizing Antibody ELISA kit” and the “Genscript cPass, kit” revealed an overall good correlation ranging from 0.8673 to −0.8773 and a midway profile between both commercial kits with 87.76% sensitivity and 90.48% clinical specificity. The BA.2-sVNT performance was similar to the BA.2 Genscript test. Finally, a correlation analysis revealed a strong association (r = 0.8583) between BA.5-sVNT and VNT sVNT using a double-vaccinated cohort (<i>n</i> = 100) and an Omicron-breakthrough infection cohort (<i>n</i> = 91). In conclusion, the sVNT allows for the efficient prediction of immune protection against the various VOCs.https://www.mdpi.com/1422-0067/24/19/14965SARS-CoV-2viral neutralization assayimmunityneutralizing antibodiesvaccines |
| spellingShingle | Eveline Santos da Silva Jean-Yves Servais Michel Kohnen Vic Arendt Therese Staub the CON-VINCE Consortium the CoVaLux Consortium Rejko Krüger Guy Fagherazzi Paul Wilmes Judith M. Hübschen Markus Ollert Danielle Perez-Bercoff Carole Seguin-Devaux Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern International Journal of Molecular Sciences SARS-CoV-2 viral neutralization assay immunity neutralizing antibodies vaccines |
| title | Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern |
| title_full | Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern |
| title_fullStr | Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern |
| title_full_unstemmed | Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern |
| title_short | Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern |
| title_sort | validation of a sars cov 2 surrogate neutralization test detecting neutralizing antibodies against the major variants of concern |
| topic | SARS-CoV-2 viral neutralization assay immunity neutralizing antibodies vaccines |
| url | https://www.mdpi.com/1422-0067/24/19/14965 |
| work_keys_str_mv | AT evelinesantosdasilva validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern AT jeanyvesservais validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern AT michelkohnen validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern AT vicarendt validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern AT theresestaub validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern AT theconvinceconsortium validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern AT thecovaluxconsortium validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern AT rejkokruger validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern AT guyfagherazzi validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern AT paulwilmes validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern AT judithmhubschen validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern AT markusollert validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern AT danielleperezbercoff validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern AT caroleseguindevaux validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern |